◆ 2018 Ph.D. student thesis defense of Suzhou Biopharmaceutical R&D center, Chinese Academy of Medical Sciences, Peking Union Medical College was held.
◆ 2017 Ph.D. student thesis defense of Suzhou Biopharmaceutical R&D center, Chinese Academy of Medical Sciences, Peking Union Medical College was held.
◆ American Association of Blood Banks (AABB) invited Xin Guan et al. of R&D center to give a subjective report in the fifth International Cord Blood Symposium (ICBS) in San Diego in June, 2017.
◆ Three research achievements of R&D center were orally presented in the 58th American society of Hematology (ASH) meeting in San Diego and won abstract awards.
◆ Three research achievements of R&D center were orally presented in the 57th American society of Hematology (ASH) meeting in Orlando and won the abstract awards.
◆ Research achievement of R&D center Ph.D. student Yu Zhang was presented in 77th Japanese Society of Hematology (JSH) meeting in Kanazawa.
◆ The 5th master student thesis defense of Suzhou Biopharmaceutical R&D center, Chinese Academy of Medical Sciences, Peking Union Medical College was held on June 25th, 2015.
◆ Three research achievements of R&D center were presented in the 2015 Experimental Biology annual meeting in Boston.
◆ Four research achievements of R&D center were presented orally in the 56th American society of Hematology (ASH) meeting in San Francisco.
◆ “Innovative Drug Incubation Base project” Workshop of Suzhou Biopharmagen. Corp. was held in Kunming, September, 2014.
◆ The 4th master student thesis defense of Suzhou Biopharmaceutical R&D center, Chinese Academy of Medical Sciences, Peking Union Medical College was held on June 25th, 2014.
 The iPS and stem cell symposium of Tianjin Institute of Hematology and Suzhou Biopharmaceutical R&D center, Chinese Academy of Medical Sciences, Peking Union Medical College was held.
◆ The workshop of Project “Construction of iPS Library and its application in hematological disorders” was jointly held with Tianjin Institute of Hematology Chinese Academy of Medical Sciences, Peking Union Medical College. 
 2013 Annual symposium of Biopharmagen. Corp. of was held.
◆ The National Post-Doctoral Research Station was established, and approved by the China Ministry of Human Resource Affairs.
 2012 Annual symposium of Biopharmagen. Corp. of was held.
 The 3rd master student thesis defense of Suzhou Biopharmaceutical R&D center, Chinese Academy of Medical Sciences, Peking Union Medical College was held.
 Recombinant gene-engineering bio-products and monoclonal antibodies came into the market in April, 2012.
◆ The first master student thesis defense of Suzhou Biopharmaceutical R&D center, Chinese Academy of Medical Sciences, Peking Union Medical College was held on May 8th, 2010.
◆ Liming Li, the Party Committee Secretary of Chinese Academy of Medical Sciences, Peking Union Medical College took an inspection on Biopharmaceutical R&D Center on February 6th, 2010.
◆ Graduate student were recruited in Biopharmaceutical R&D Center, Chinese Academy of Medical Sciences, Peking Union Medical College.
◆ Postdoctoral researchers were recruited in Suzhou Biopharmagen. Corp.
◆ The founder received “ Outstanding Entrepreneur Award” of one hundred Chinese oversea professionals of China in September, 2005.
◆ Biopharmagen. Corp. was elected “Top 50 Enterprises with Foreign Investment of Guangxi” in 2001.
◆ Biopharmagen. Corp. was awarded honest taxpayer by the State Tax Bureau of Guangxi Zhuang Autonomous Region.
◆ Biopharmagen. Corp. is rated high-tech enterprises by the National Ministry of Science and Technology and Department of Science and Technology of Guangxi District, respectively in September, 2000.
◆ The second generation of new rhG-CSF was developed and selected as a priority project of “National 863 Program” industrialization projects.
◆ Recombinant human granulocyte colony stimulating factor (rhG-CSF), was identified as a high-tech product by Department of Science and Technology of Guangxi in January, 2000.
◆ In 2000, The National Post-Doctoral Research Station was established, and approved by the China Ministry of Human Resource Affairs.
◆ Recombinant human granulocyte colony stimulating factor (rhG-CSF), was listed in the “National Torch Program” in 1999.
◆ We have received GMP of G-CSF (first generation) production line certified by CFDA in December, 1999.
◆ In November 1999,rhG-CSF was broadcasted in CCTV “Scientific Expo” program: “the representative of the gene-engineering drugs – rhG-CSF is an outstanding representative in treatment of cancers.”
◆ Recombinant human granulocyte colony stimulating factor (rhG-CSF), the first product was developed independently by Biopharmagen. Corp. and identified as “National New Product” by National Ministry of Economic Relations and Trade in 1997.
◆ Biopharmagen. Corp. is awarded Advanced Technical Enterprise with foreign investment in November, 1997.

Biopharmagen Corp., Fangzhou Suzhou.          Tel:0512-62831269          Email:Suzhou@Biopharmagen.com